Stephen J. Denelsky, who serves on the board of Harvard Bioscience Inc. (NASDAQ: HBIO), purchased 10,000 shares of the company on March 17, 2026, at a price of $4.87 per share. The total consideration for the stake was $48,700. At the time of reporting, the company's shares were trading at $4.74 and were down 27% year-to-date, although analysts continue to point to a $6.00 price target.
Following the purchase, Denelsky directly holds 21,000 shares in Harvard Bioscience. That total includes 11,000 restricted stock units, which the filing indicates will fully vest on September 5, 2026. The restricted stock units were adjusted to reflect the company 10-for-1 reverse stock split that took effect on March 13, 2026, according to the filing.
The filing also highlights the company's short-term liquidity position. Data cited from InvestingPro notes that Harvard Bioscience has liquid assets in excess of its short-term obligations, reflected in a current ratio of 2.2.
On the operating front, Harvard Bioscience released fourth-quarter 2025 results showing revenue of $23.7 million. That figure exceeded the midpoint of the company's guidance range for the quarter but represented a 3.2% decline versus the prior year. Gross margin for the period was reported at 59.77%, the highest level recorded in seven quarters.
For full-year 2026, management is guiding to revenue growth of 2% to 4%, which translates to a range of $88 million to $90 million. The firm expects gross margins to be between 58% and 60%, and adjusted EBITDA growth of 6% to 10%, or $8.6 million to $8.9 million.
Analyst coverage reflects mixed sentiment. Benchmark recently adjusted its price target to $6.00 from $0.60 following the company's 1-for-10 reverse stock split and retained a Speculative Buy rating. In its commentary, Benchmark cited the company's strategic priorities around manufacturing consolidation and anticipated revenue gains from the New Product Innovation pipeline. The same firm had earlier cut its price target to $0.60 from $2.00 amid concerns tied to NIH budget dynamics and what it described as a conservative outlook for 2026. These changes illustrate divergent analyst views on the company's trajectory.
This insider transaction, the recent reverse split and the published 2026 guidance together provide investors with updated data points on Harvard Bioscience's financial position and management priorities. The filing documents and reported quarterly results form the factual basis for assessing the company's short-term liquidity and its revenue and margin assumptions for the year ahead.